Clinical trials: HIV/AIDS
HIV Infections, Pregnancy Related
PrEP Implementation for Mothers in Antenatal Care
In a region with 15-20% HIV prevalence, an estimated 20% of HIV-uninfected women could have HIV exposures in pregnancy. In a theoretical scenario of perfect PrEP coverage, all women at risk receive PrEP while no women not at HIV…
- Trial name
- PrIMA (NCT03070600)
- Testing
- Universal PrEP Counseling, Targeted PrEP Counseling
- Where
- 20 sites in Kenya
- Volunteers
- 4,447 people
- Sponsor
- University of Washington
HIV Prevention, Transgender Health
Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy
Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012. Drug concentrations after receipt of oral Truvada for HIV Pre Exposure Prophylaxis (or PrEP) appeared to be…
- Trial name
- I-BrEATHe (NCT04050371)
- Testing
- 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV/AIDS, Albuminuria
Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
In this study, the Investigators plan to determine the optimal means to prevent or slow the progression of kidney disease among genetically at-risk northern Nigerian HIV-infected adults.
- Conditions
- HIV/AIDS, Albuminuria, Kidney Diseases, Genetic Predisposition
- Trial name
- R3 (NCT03201939)
- Testing
- Lisinopril
- Where
- Nigeria
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
HIV Infections
Young Men's Health Project Targeting HIV Risk Reduction and Substance Abuse
YMHP is a counseling intervention program for which the goals are to better understand HIV-prevention focused self-management behaviors among HIV-negative YMSM, and to study the implementation of YMHP to improve portability and…
- Trial name
- YMHP (NCT03577301)
- Testing
- Clinic-based Delivery, Remote Delivery, Multi-modal Delivery
- Where
- 3 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Florida State University
HIV Infections
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels of each other when given separately and…
- Trial name
- NCT00982553
- Testing
- Ribavirin, Raltegravir
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Trichomonas Infections, HIV Infections
Trichomonas Vaginalis Recurrence Among HIV+ Women
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
- Trial name
- NCT01018095
- Testing
- Metronidazole
- Where
- 5 sites in United States
- Volunteers
- 270 people
- Sponsor
- Tulane University Health Sciences Center
HIV Infections
Pain and Sensory Changes Assessment in HIV+ Patients
There are about 42 million people in the world afflicted with HIV or AIDS with about 1 million patients in the US. The epidemiology of orofacial pain has been reported extensively in the literature, yet the prevalence severity…
- Trial name
- NCT00422695
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Dentistry of New Jersey
HIV, Hepatitis C
A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
The CTSI-PLACE Study is a study for men and women with HIV/hepatitis C co-infection or HIV only. The study looks at the impact of having hepatitis C virus in addition to HIV on risk for cardiovascular disease.
- Trial name
- CTSI-PLACE (NCT02597790)
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of California, Los Angeles
HIV, Depression
HIV Translating Initiatives for Depression Into Effective Solutions
This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.
- Trial name
- HI-TIDES (NCT00304915)
- Testing
- Collaborative Care Interventions
- Where
- 3 sites in United States
- Volunteers
- 249 people
- Sponsor
- VA Office of Research and Development
Influenza
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
The purpose of this study is to see how the body reacts to different strengths of the H1N1 flu shot in persons infected with human immunodeficiency virus (HIV).
- Trial name
- NCT00992433
- Testing
- Inactivated Influenza H1N1 vaccine
- Where
- 6 sites in United States
- Volunteers
- 192 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. H56:IC31 (investigational vaccine) Placebo 900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are…
- Trial name
- NCT03512249
- Testing
- H56:IC31
- Where
- 6 sites in South Africa, Tanzania
- Volunteers
- 831 people
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population
The purpose of this study is to evaluate the safety of and adherence to a vaginal matrix ring (VR) containing dapivirine and oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in adolescent and young adult females.
- Trial name
- NCT03593655
- Testing
- Dapivirine vaginal ring, FTC/TDF
- Where
- 4 sites in South Africa, Uganda and 1 more
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Antiretroviral Improvement Among Medicaid Enrollees
This study will evaluate whether a new program will affect how often human immunodeficiency virus (HIV) antiretroviral therapy (ART) prescriptions are filled and whether the program improves the health of people living with HIV.
- Trial name
- AIMS (NCT05477485)
- Testing
- Experimental: AIMS program - patient, No Intervention/Usual care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
HIV
Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
The project presented here will be the first prospective, randomized evaluation of the effect of ART on the structure and function of the gut microbiome.
- Trial name
- NCT03029689
- Testing
- Raltegravir, Current ART
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV Prevention
Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya
Few young women at risk of HIV infection are initiating pre-exposure prophylaxis (PrEP) for HIV prevention in Kenya, thus we propose refining and testing a new model to increase PrEP initiation among young women at high HIV risk…
- Trial name
- PeerPrEP (NCT04982250)
- Testing
- Enhanced peer PrEP referral + HIVST delivery
- Where
- Kenya
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Non Communicable Diseases, HIV
Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia
This mixed-methods formative research study aims to adapt the WHO Package of Essential Noncommunicable Disease Interventions (WHO-PEN) approach for the Zambian public health system, and pilot test an adapted, streamlined, and…
- Trial name
- TASKPEN (NCT05005130)
- Testing
- TASKPEN
- Where
- 4 sites in Zambia
- Volunteers
- 1,129 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Alcohol Use Disorder, HIV-infection/Aids
Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda
Fisherfolk are a high risk population for HIV and are prioritized to receive antiretroviral treatment (ART) in Uganda, but risky alcohol use among fisherfolk is a barrier to HIV care engagement; multilevel factors influence…
- Trial name
- NCT03919695
- Testing
- Kisoboka: Behavioral and Structural Intervention, Screening and Referral
- Where
- Uganda
- Volunteers
- 160 people
- Sponsor
- San Diego State University
HIV Infections
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human…
- Trial name
- NCT01622673
- Testing
- Raltegravir, TUMS® Ultra Strength, MINTOX® Maximum Strength
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with…
- Trial name
- NCT02788045
- Testing
- Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140
- Where
- 10 sites in United States, Rwanda
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.